GlassScriptPhysician profile
Jayme B Williams
NPI 1972792224
$21,243.68
in general payments reported to CMS, 2019-2025
33 companies · $4,993 in 2025
The $4,993 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,054 · 2022: $3,653 · 2023: $3,740 · 2024: $4,803 · 2025: $4,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,167.44 |
| Education | $368.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,449.94 | 2021-2025 | |
| Janssen Biotech, INC. | $2,602.47 | 2021-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $1,706.03 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,382.13 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,175.17 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $1,174.01 | 2021-2025 | |
| Genzyme Corporation | $1,153.91 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,010.29 | 2022-2024 | Vtama |
| Ucb, INC. | $1,003.73 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $820.16 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $792.98 | 2021-2025 | Otezla |
| Pfizer INC. | $742.63 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $640.41 | 2022-2025 | Sotyktu |
| Incyte Corporation | $537.57 | 2021-2025 | Opzelura, Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $455.17 | 2021-2025 | Siliq, Duobrii, Targretin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $430.04 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Organon LLC | $390.56 | 2025 | Vtama |
| Almirall LLC | $282.28 | 2021-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $276.19 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $252.15 | 2023-2024 | Ycanth |
| Journey Medical Corporation | $169.09 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.77 | 2023-2025 | Spevigo, Cyltezo |
| Epi Health, LLC | $130.44 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $117.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Paratek Pharmaceuticals, INC. | $89.90 | 2022-2024 | Nuzyra |
| Nabriva Therapeutics, Plc | $58.40 | 2021-2022 | |
| Botanix Sb INC | $41.44 | 2025 | Sofdra |
| Genentech USA, INC. | $26.42 | 2025 | Xolair |
| Kyowa Kirin, INC. | $24.55 | 2022 | |
| Sebela Pharmaceuticals INC. | $21.79 | 2022 | |
| Celgene Corporation | $17.49 | 2021 | |
| Dermira, INC. | $16.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayme Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.